![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
5MB |
![[thumbnail of Supplementary Data]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Data)
12MB |
| Item Type: | Article |
|---|---|
| Title: | Integrated proteomics unveils nuclear PDE3A2 as a regulator of cardiac myocyte hypertrophy |
| Creators Name: | Subramaniam, G., Schleicher, K., Kovanich, D., Zerio, A., Folkmanaite, M., Chao, Y.C., Surdo, N.C., Koschinski, A., Hu, J., Scholten, A., Heck, A.J.R, Ercu, M., Sholokh, A., Chan Park, K., Klussmann, E., Meraviglia, V., Bellin, M., Zanivan, S., Hester, S., Mohammed, S. and Zaccolo, M. |
| Abstract: | BACKGROUND: Signaling by cAMP is organized in multiple distinct subcellular nanodomains regulated by cAMP-hydrolyzing PDEs (phosphodiesterases). Cardiac ß-adrenergic signaling has served as the prototypical system to elucidate cAMP compartmentalization. Although studies in cardiac myocytes have provided an understanding of the location and properties of a handful of cAMP subcellular compartments, an overall view of the cellular landscape of cAMP nanodomains is missing. METHODS: Here, we combined an integrated phosphoproteomics approach that takes advantage of the unique role that individual PDEs play in the control of local cAMP, with network analysis to identify previously unrecognized cAMP nanodomains associated with ß-adrenergic stimulation. We then validated the composition and function of one of these nanodomains using biochemical, pharmacological, and genetic approaches and cardiac myocytes from both rodents and humans. RESULTS: We demonstrate the validity of the integrated phosphoproteomic strategy to pinpoint the location and provide critical cues to determine the function of previously unknown cAMP nanodomains. We characterize in detail one such compartment and demonstrate that the PDE3A2 isoform operates in a nuclear nanodomain that involves SMAD4 (SMAD family member 4) and HDAC-1. Inhibition of PDE3 results in increased HDAC-1 phosphorylation, leading to inhibition of its deacetylase activity, derepression of gene transcription, and cardiac myocyte hypertrophic growth. CONCLUSIONS: We developed a strategy for detailed mapping of subcellular PDE-specific cAMP nanodomains. Our findings reveal a mechanism that explains the negative long-term clinical outcome observed in patients with heart failure treated with PDE3 inhibitors. |
| Keywords: | Phosphoric Diester Hydrolases, Rodentia, Hypertrophy, Protein Isoforms, Adrenergic Agents |
| Source: | Circulation Research |
| ISSN: | 0009-7330 |
| Publisher: | American Heart Association |
| Volume: | 132 |
| Number: | 7 |
| Page Range: | 828-848 |
| Date: | 31 March 2023 |
| Official Publication: | https://doi.org/10.1161/circresaha.122.321448 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
